Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Elan agrees to $8.3bn acquisition by Perrigo

Executive Summary

In its most expensive acquisition to date, OTC and generics firm Perrigo Co. is buying publicly traded Elan Corp. PLC for $8.3bn. For each Elan share (approximately 511.8mm), Perrigo will pay $6.25 in cash and issue 0.07636 in stock, equating to $16.17 per share, a 57% premium to Elan’s ten-day average prior to the February 2013 Royalty Pharma announcement.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register